Esaote to Be Acquired by Consortium of Chinese Healthcare Companies

Esaote S.p.A. (Genoa, Italy) has entered into definitive agreements with a consortium of Chinese investors who will acquire the entire share capital of the company. The consortium acquiring Esaote comprises leading medical technology and healthcare companies, as well as financial investors with significant experience in the healthcare sector.

Esaote is a diagnostic imaging company with particular focus on the areas of ultrasound, dedicated MRI and software for managing the diagnostic process. The Chinese consortium will acquire 100% of the outstanding shares of Esaote, which will continue to operate as an independent global medical equipment company. The consortium will leverage their distribution networks to increase Esaote’s penetration in the Chinese medical imaging equipment market, while the company will distribute the consortium’s relevant medical products in the international markets where it operates.

While Esaote will receive enhanced access to the large and rapidly expanding Chinese medical equipment market, the consortium will benefit from the company’s strong R&D capabilities, globally recognized brand and product lines, and extensive international distribution network in the medical imaging sector.

“What we have achieved, with the investment and expertise of our shareholders, has produced important gains for Esaote over these last three years. Now we are ready to embark on an exciting next journey for the company with the support of our new shareholders, who are highly committed to the healthcare industry and see a great future for Esaote,” said Mr. Karl-Heinz Lumpi, CEO of Esaote. “We look forward to learning from and leveraging their deep knowledge and experience of the Chinese market where the potential for growth is significant, especially considering that the ultrasound sector alone is worth nearly EUR 1.3 billion in China.”